Why the study?
Does resveratrol improve cardiac hypertrophy and reduce angiotensin II receptor transcription in a rat model of pressure overload?
Does resveratrol improve cardiac hypertrophy and reduce angiotensin II receptor transcription in a rat model of pressure overload?
Resveratrol protects against cardiac hypertrophy progression in a rat model, partly by reducing cardiac AT1a transcription.
Resveratrol effects in rat hypertrophy are hypothesis-generating; leaves open translation to human pressure-overload states.
This study investigated the effect of resveratrol on serum and cardiac levels of angiotensin II and transcription of its main receptors following pressure overload induced-hypertrophy. Rats were divided into untreated (Hyp) and resveratrol treated hypertrophied groups (H + R). Intact animals served as the control (Ctl). Cardiac hypertrophy was induced by abdominal aortic banding. Blood pressure (BP) was recorded via left carotid artery cannula. Fibrosis was confirmed by Masson trichrome staining. Angiotensin II level was measured using an ELIZA test. Gene expression was assessed by a real time PCR (RT-PCR) technique. We observed that in the H + R group BP and heart weight/body weight were decreased significantly (p < 0.001, p < 0.05, respectively vs Hyp). The cardiac levels of angiotensin II and AT1a mRNA were increased in the Hyp group (p < 0.01 vs Ctl). In the H + R group the AT1a mRNA level was decreased significantly (p < 0.05 vs Hyp). It could be concluded that resveratrol protects the heart against hypertrophy progression in part by affecting cardiac AT1a transcription.
No takes yet. Share an insight, caveat, or question.
Mashhadi et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: